Considering CCT6A was an important member of TRiC and had shown an oncogenic effect on cellular functions (including NSCLC), meanwhile, it was correlated with unfavorable progression and prognosis in cancer patients, we hypothesized that CCT6A might affect TRiC function and eventually correlated with disease progression in NSCLC patients, while no relative clinical research was done yet. Here, MARVELD2 is linked to cancer.